Ozempic Archives -

Eli Lilly has scored five out of five with its phase 3 trials of type 2 diabetes candidate

Trial win sets up filings for Lilly’s diabetes blockbuster hope tirzepatide

https://pharmaphorum.com/news/final-trial-win-sets-up-filings-for-lillys-diabetes-blockbuster-hope-tirzepatide/

Market Access/ News/ News

FDA approves MACE label claim for Lilly’s Trulicity

Phil Taylor Diabetes, Eli Lilly, Novo Nordisk, Ozempic, Rybelsus, Trulicity 0 Comment

Eli Lilly has firmed up the label for its type 2 diabetes therapy Trulicity with FDA approval for

FDA approves MACE label claim for Lilly’s Trulicity

https://pharmaphorum.com/news/fda-approves-mace-label-claim-for-lillys-trulicity/

News/ News/ Sales and Marketing

Ozempic acceleration buoys Novo Nordisk, and threatens Lilly

Phil Taylor Diabetes, Eli Lilly, financial results, Novo Nordisk, Ozempic, Rybelsus, Saxenda, Trulicity 0 Comment

Solid growth for Novo Nordisk’s weekly GLP-1 agonist Ozempic in the fourth quarter helped the Danish drugmaker beat

Ozempic acceleration buoys Novo Nordisk, and threatens Lilly

https://pharmaphorum.com/news/ozempic-acceleration-buoys-novo-nordisk-and-threatens-lilly/

News/ News/ Sales and Marketing/ Top stories

Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge

Phil Taylor Diabetes, Eli Lilly, financial results, Novo Nordisk, Ozempic, Rybelsus, Trulicity 0 Comment

Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but

Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge

https://pharmaphorum.com/news/lillys-diabetes-med-trulicity-shrugs-off-novo-nordisk-challenge/

Market Access/ News/ News

Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome

Phil Taylor Diabetes, metabolic diseases, Novo Nordisk, Ozempic, semaglutide 0 Comment

The FDA approval last Friday of Novo Nordisk’s Rybelsus as the first orally-active GLP-1 agonist is only the

Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome

https://pharmaphorum.com/news/novos-new-oral-glp-1-still-has-obstacles-to-overcome/

News/ Novo Nordisk

Novo Nordisk hints at US price cuts after Q2 sales fall

Piotr Wnuk Donald Trump, Novo Nordisk, Ozempic, Victoza, Xultrophy 0 Comment

Danish pharma Novo Nordisk posted second-quarter operating profit in line with forecasts but hinted about the possibility of

Novo Nordisk hints at US price cuts after Q2 sales fall

https://pharmaphorum.com/news/novo-nordisk-price-reductions/

News/ News/ R&D/ Sales and Marketing

Trulicity helps SGLT-2 patients lower blood sugar

Andrew McConaghie Diabetes, Eli Lilly, Novo Nordisk, Ozempic, Trulicity, Type 2 diabetes 0 Comment

New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.

Trulicity helps SGLT-2 patients lower blood sugar

https://pharmaphorum.com/news/trulicity-sglt-2-drug-combo-doesnt-boost-blood-sugar-lowering/

Diabetes/ Market Access/ News/ News

Novo Nordisk undeterred after losing out on Ablynx takeover

Andrew McConaghie Ablynx, Diabetes, Novo Nordisk, Ozempic 0 Comment

After losing out to Sanofi in its pursuit of Belgian biotech Ablynx earlier this week, Novo Nordisk has put a brave face on the disappointment.

Novo Nordisk undeterred after losing out on Ablynx takeover

https://pharmaphorum.com/news/novo-nordisk-undeterred-losing-ablynx-takeover/

Trending

Ozempic

Login